クラドリビン
参考資料

↑  “Cladribine”. Drugs.com (28 February 2020). 4 March 2020閲覧。
↑  Liliemark, Jan (1997). “The Clinical Pharmacokinetics of Cladribine”. Clinical Pharmacokinetics 32 (2):  120–131. doi:10.2165/00003088-199732020-00003. PMID 9068927.
1 2 3 4  “PRODUCT INFORMATION LITAK© 2 mg/mL solution for injection” (PDF). TGA eBusiness Services.  St Leonards, Australia:  Orphan Australia Pty. Ltd (10 May 2010). 27 November 2014閲覧。
1 2   European Medicines Agency - - Litak. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000504/human_med_000888.jsp&mid=WC0b01ac058001d124.
1 2   Leustat Injection. - Summary of Product Characteristics (SPC) - (eMC). http://www.medicines.org.uk/emc/medicine/6737.
↑  Leist, TP; Weissert, R (2010). “Cladribine: mode of action and implications for treatment of multiple sclerosis.”. Clinical Neuropharmacology 34 (1):  28–35. doi:10.1097/wnf.0b013e318204cd90. PMID 21242742.
↑  “ヤンセン　ファーマ　抗悪性腫瘍剤「ロイスタチン注」の輸入承認を取得”.   株式会社じほう. 2021年3月26日閲覧。
↑  “ヤンセン ファーマ　　ロイスタチンの適応追加 | ニュース | ミクスOnline”. www.mixonline.jp. 2021年3月26日閲覧。
↑  “Cladribine- cladribine injection”. DailyMed (31 December 2019). 4 March 2020閲覧。
↑  “Mavenclad- cladribine tablet”. DailyMed (10 April 2019). 4 March 2020閲覧。
↑  “FDA approves new oral treatment for multiple sclerosis”. U.S. Food and Drug Administration (FDA) (29 March 2019). 4 March 2020閲覧。
↑  Histiocytosis Association Erdheim-Chester Disease Archived 2019-06-06 at the Wayback Machine. Page accessed Aug 20, 2016
↑  Aricò M (2016). “Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy”. Br J Haematol 173 (5):  663–70. doi:10.1111/bjh.13955. PMID 26913480. "The combination of cytarabine and cladribine is the current standard for second-line therapy of refractory cases with vital organ dysfunction."
↑  “ロイスタチン注8mg 添付文書”. www.info.pmda.go.jp.   PMDA. 2021年3月26日閲覧。
1 2 3  Giovannoni, G; Comi, G; Cook, S; Rammohan, K; Rieckmann, P; Soelberg Sørensen, P; Vermersch, P; Chang, P et al. (4 February 2010). “A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.”. The New England Journal of Medicine 362 (5):  416–26. doi:10.1056/NEJMoa0902533. PMID 20089960.
↑  Johnston, JB (June 2011). “Mechanism of action of pentostatin and cladribine in hairy cell leukemia.”. Leukemia & Lymphoma 52 Suppl 2:  43–5. doi:10.3109/10428194.2011.570394. PMID 21463108.
↑  Beutler, E; Piro, LD; Saven, A; Kay, AC; McMillan, R; Longmire, R; Carrera, CJ; Morin, P et al. (1991). “2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.”. Leukemia & Lymphoma 5 (1):  1–8. doi:10.3109/10428199109068099. PMID 27463204.
↑  Baker, D; Marta, M; Pryce, G; Giovannoni, G; Schmierer, K (February 2017). “Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.”. EBioMedicine 16:  41–50. doi:10.1016/j.ebiom.2017.01.042. PMC 5474520. PMID 28161400. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474520/.
↑  Baker, D; Herrod, SS; Alvarez-Gonzalez, C; Zalewski, L; Albor, C; Schmierer, K (July 2017). “Both cladribine and alemtuzumab may effect MS via B-cell depletion.”. Neurology: Neuroimmunology & Neuroinflammation 4 (4):  e360. doi:10.1212/NXI.0000000000000360. PMC 5459792. PMID 28626781. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459792/.
1 2  Ceronie, B; Jacobs, BM; Baker, D; Dubuisson, N; Mao, Z; Ammoscato, F; Lock, H; Longhurst, HJ et al. (May 2018). “Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.”. Journal of Neurology 265 (5):  1199–1209. doi:10.1007/s00415-018-8830-y. PMC 5937883. PMID 29550884. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937883/.
1 2  Giovannoni, G; Soelberg Sorensen, P; Cook, S; Rammohan, K; Rieckmann, P; Comi, G; Dangond, F; Adeniji, AK et al. (1 August 2017). “Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.”. Multiple Sclerosis (Houndmills, Basingstoke, England) 24 (12):  1594–1604. doi:10.1177/1352458517727603. PMID 28870107.  オリジナルの10 March 2020時点におけるアーカイブ。. https://web.archive.org/web/20200310002303/https://curis.ku.dk/ws/files/216467861/1352458517727603.pdf.
↑  “Sustained Efficacy - Merck Neurology”. Merck Neurology. 28 September 2018閲覧。
↑  Guarnera, C; Bramanti, P; Mazzon, E (2017). “Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.”. Therapeutics and Clinical Risk Management 13:  871–879. doi:10.2147/TCRM.S134398. PMC 5522829. PMID 28761351. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522829/.
↑  Baker, D; Herrod, SS; Alvarez-Gonzalez, C; Giovannoni, G; Schmierer, K (1 August 2017). “Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.”. JAMA Neurology 74 (8):  961–969. doi:10.1001/jamaneurol.2017.0676. PMC 5710323. PMID 28604916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710323/.
↑  “Cladribine tablets for treating relapsing–remitting multiple sclerosis”. National Institute for Clinical Excellence. 23 September 2018閲覧。
↑  Hasanali, Zainul S.; Saroya, Bikramajit Singh; Stuart, August; Shimko, Sara; Evans, Juanita; Shah, Mithun Vinod; Sharma, Kamal; Leshchenko, Violetta V. et al. (24 June 2015). “Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia”. Science Translational Medicine 7 (293):  293ra102. doi:10.1126/scitranslmed.aaa5079. ISSN 1946-6234. PMC 4807901. PMID 26109102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807901/.